Zura Bio Ltd (ZURA)
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Zura Bio Limited
NASDAQ:ZURAHealthcare · Biotechnology
AHAfter hours-0.48%$1.03
Prev close$1.08-4.17%Close$1.03-0.48%Now$1.03
Close$1.03-4.17%
Mkt Cap$99.7M
EV-
Float68.65M
O/S96.33M
VOL3.52M sh
$ Vol$3.58M
RVOL0.47×
Inst Own71.9%
Net Cash/Sh-
EarningsMar 31 · in 4mo
Dilution
MCap$99.7MFloat68.65MO/S96.33M
Dilution
1-25 of 447 filings
…
Recent SEC filings with analysis
- S-3Zura Bio filed a $700 million universal shelf registration statement covering Class A ordinary shares, preference shares, debt securities, warrants and units,…
- 8-KZura Bio reported Q3 2026 results with a net loss of $25.8 million ($0.20 per share) versus $18.0 million a year ago, as R&D spend rose to $19.5 million from…
- 10-QZura Bio reported a Q3 2026 net loss of $25.8 million ($0.20 per share), with losses widening 43% year over year as R&D spending jumped 63% to $19.5 million to…